Other

Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet

Universitat Leipzig

Eberhard Karls Universitat Tubingen Medizinische F Akultat

Gleiter, Christoph H.

Danielyan, Lusine

Frey Ii, William H.

Lusine Danielyan

Christoph Gleiter

William Howard Frey, Ii

Matthias Schwab

Richard Schäfer

Gayane Buniatian

Barbara Proksch

Rolf Gebhardt

Hans-Peter Wendel

Rainer Kehlbach

Hinnak Northoff

Claus Claussen

Torsten Kluba

Andreas Von Ameln-Mayerhofer

Ruediger Bantleon

Richard Schaefer

Christoph H Gleiter

William H Frey Ii

Christoph Hermann Gleiter

The present invention relates to a method for the in vitro selection of at least one therapeutic cell subpopulation from an original cell population of eukaryotic cells, as well as to the therapeutic cell subpopulation selected by the method, which can be used for the treatment of diseases of tissues or organs. The selected cells are highly migrative and the method according to the invention provides for the selection of these highly migrative subpopulations from a sample comprising a mixture of cells.

Cell selection method and cells obtained therefrom

Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.

Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.

Use of the opposite cell differentiation program (OCDP) for the treatment of degenerated organs in the pathological state

Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.

Growing community of inventors

Tuebingen, Germany

Lusine Danielyan